Title : Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

Pub. Date : 2021 May 10

PMID : 33449813






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. hypomethylating agents tumor protein p53 Homo sapiens